Oxypeucedanin
Based on 1 Customer Validation
Oxypeucedanin is a furanocoumarin derivative found in Angelica dahurica. Oxypeucedanin is an orally active PI3K/AKT/NF-κB, MAPK, and ROS inhibitor. Oxypeucedanin induces cell cycle arrest and apoptosis. Oxypeucedanin inhibits hKv1.5 channel currents (IC50: 76 nM). Oxypeucedanin exhibits anticancer, anti-inflammatory, antioxidant and antiarrhythmic activities.
For research use only. We do not sell to patients.
- Purity: 99.50%
- CAS No.: 737-52-0
- Formula: C16H14O5
- Molecular Weight:286.28
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Biological Activity
IC50: HKv1.5 current; apoptosis[1]
oxypeucedanin (1-1000 nM) inhibits hKv1.5 channel currents expressed in the mouse Ltk- cell lines in a concentration-dependent manner (IC50: 76 nM)[1].
oxypeucedanin (0.1-1 μM) prolongs the action potential duration (APD) of rat atrial and ventricular myocytes in a concentration-dependent manner[1].
Oxypeucedanin (25-100 μM, 24-72 h) inhibits the viability of human prostate cancer DU145 cells and induces apoptosis in a time- and dose-dependent manner[2].
Oxypeucedanin (25-100 μM, 24-48 h) induces G2-M arrest in DU145 cell cycle progression in a dose-dependent manner[2].
Oxypeucedanin (6.25-12.5 μM, 7-13 h) inhibits the expression of inflammatory factors IL-6, IL-1β, TNF-α, iNOS, COX-2 and the production of ROS in RAW264.7 cells[3].
Oxypeucedanin (6.25-12.5 μM, 2 h) inhibits the PI3K/AKT/NF-κB and MAPK signaling pathways in RAW264.7 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:DU145 cells
-
Concentration:25, 50 and 100 μM
-
Incubation Time:24, 48 and 72 h
-
Result:Inhibited cell growth.
Induced cell death.
-
Cell Line:DU145 cells
-
Concentration:25, 50 and 100 μM
-
Incubation Time:24, 48 and 72 h
-
Result:Decreased the protein levels of Cdc-25C, Cyclin A, Cyclin B1 and Cdc-2.
Increased the protein levels of Chk1, Chk2, cleaved caspase-3 and cleaved PARP.
-
Cell Line:RAW264.7 cells
-
Concentration:6.25 and 12.5 μM
-
Incubation Time:2, 13 h
-
Result:Decreased the protein levels of iNOS and COX-2.
Inhibited the phosphorylation levels of AKT, P65, P38, ERK1/2 and JNK proteins and the ubiquitination degradation of IκB proteins.
-
Cell Line:RAW264.7 cells
-
Concentration:6.25 and 12.5 μM
-
Incubation Time:7 h
-
Result:Down-regulated the mRNA levels of inflammatory factors iNOS, COX-2, IL-6, IL-1β, and TNF-α.
| Species | Dose | Route | Plasma Concentration | AUC | MRT | Tmax | Bioavailability |
|---|---|---|---|---|---|---|---|
| Rat[5] | 10 mg/kg | i.v. | 1662.94 μg/L | 1.28 mg·h/L | 0.80 h | / | / |
| Rat[5] | 2.5 mg/kg | i.v. | 1140.35 μg/L | 0.48 mg·h/L | 0.62 h | / | / |
| Rat[5] | 20 mg/kg | i.g. | 64.64 μg/L | 0.28 mg·h/L | 5.86 h | 3.38 h | 10.26 % |
| Rat[5] | 5 mg/kg | i.v. | 1393.22 μg/L | 0.76 mg·h/L | 0.72 h | / | / |
Oxypeucedanin (13.5 mg/kg, p.o.) alleviates the severity of collagen-induced arthritis (CIA) model in rats[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:LPS-induced ALI mouse model (75 male BALB/c mice, ages 6-8 weeks and weights of 20-25 g; unilateral nostril drops were added to the 50 μg LPS solution to establish the ALI model)[3]
-
Dosage:10 and 15 mg/kg
-
Administration:Intraperitoneal injection (i.p.), once
-
Result:Reduced lung pathological tissue damage.
Down-regulated the mRNA levels of inflammatory factors iNOS, COX-2, IL-6, IL-1β, and TNF-α.
Increased the protein levels of Occludin and Claudin 3.
-
Animal Model:Rat CIA model (Male Wistar rats, subcutaneously injected with 200/100 μL emulsion that contained 2 mg/mL chicken type II collagen (HY-NP113) and complete/incomplete Freund’s adjuvant)[4]
-
Dosage:13.5 mg/kg
-
Administration:Oral gavage (p.o.)
-
Result:Reduced swelling, redness and bone erosions.
Increased talus volume.
Chemical Information
-
CAS No. 737-52-0
-
Appearance Solid
-
Molecular Weight 286.28
-
Formula C16H14O5
-
Color White to off-white
-
SMILES
CC1(C)C(O1)COC2=C(C=CO3)C3=CC(O4)=C2C=CC4=O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
DMSO : 12.5 mg/mL (43.66 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.73 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (285 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Eun JS, et al. Effects of oxypeucedanin on hKv1.5 and action potential duration. Biol Pharm Bull. 2005 Apr;28(4):657-60. [Content Brief]
[2]. Kang TJ, et al. Anti-tumor activity of oxypeucedanin from Ostericum koreanum against human prostate carcinoma DU145 cells. Acta Oncol. 2009;48(6):895-900. [Content Brief]
[3]. Du L, et al. Oxypeucedanin relieves LPS-induced acute lung injury by inhibiting the inflammation and maintaining the integrity of the lung air-blood barrier. Aging (Albany NY). 2022 Aug 18;14(16):6626-6641. [Content Brief]
[4]. Liu M, et al. Oxypeucedanin hydrate alleviates rheumatoid arthritis by inhibiting the TLR4-MD2/NF-κB/MAPK signaling axis. Acta Biochim Biophys Sin (Shanghai). 2024 May 11;56(12):1789-1801. [Content Brief]
[5]. Zheng MC, et al. Preclinical Pharmacokinetics and Bioavailability of Oxypeucedanin in Rats after Single Intravenous and Oral Administration. Molecules. 2022 Jun 2;27(11):3570. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.4931 mL | 17.4654 mL | 34.9308 mL | 87.3271 mL |
| 5 mM | 0.6986 mL | 3.4931 mL | 6.9862 mL | 17.4654 mL | |
| 10 mM | 0.3493 mL | 1.7465 mL | 3.4931 mL | 8.7327 mL | |
| 15 mM | 0.2329 mL | 1.1644 mL | 2.3287 mL | 5.8218 mL | |
| 20 mM | 0.1747 mL | 0.8733 mL | 1.7465 mL | 4.3664 mL | |
| 25 mM | 0.1397 mL | 0.6986 mL | 1.3972 mL | 3.4931 mL | |
| 30 mM | 0.1164 mL | 0.5822 mL | 1.1644 mL | 2.9109 mL | |
| 40 mM | 0.0873 mL | 0.4366 mL | 0.8733 mL | 2.1832 mL |